Market Place
Sourcing Support
Kelun-Biotech`s TROP2 ADC sac-TMT Study Results Published
10 Jun 2025 //
PR NEWSWIRE
Sac-TMT + Tagitanlimab Gets BTD for NSCLC in China
10 Jun 2025 //
PR NEWSWIRE
British Medical Journal Study on Sacituzumab Tirumotecan for EGFR
06 Jun 2025 //
PR NEWSWIRE
Kelun-Biotech Announces Approximately US$250 Million Placement
05 Jun 2025 //
PR NEWSWIRE
Kelun-Biotech`s 6 Clinical Study Abstracts at 2025 ASCO Meeting
23 May 2025 //
PR NEWSWIRE
Kelun-Biotech`s TROP2 ADC sac-TMT NDA Accepted by CDE
21 May 2025 //
PR NEWSWIRE
Kelun-Biotech to Present Six Clinical Studies at 2025 ASCO Meeting
24 Apr 2025 //
PR NEWSWIRE
Kelun-Biotech`s ADC drug SKB518 granted IND clearance by FDA
21 Apr 2025 //
PR NEWSWIRE
Kelun`s Sacituzumab Tirumotecan Approved By NMPA For EGFRm NSCLC
10 Mar 2025 //
PR NEWSWIRE
Kelun-Biotech`s Sacituzumab Tirumotecan Results at ASCO Symposium
13 Feb 2025 //
PR NEWSWIRE
Kelun-Biotech`s Tagitanlimab Approved For Recurrent NPC Treatment
23 Jan 2025 //
PR NEWSWIRE
Kelun-Biotech Licenses SKB378/HBM9378 Anti-TSLP Monoclonal Antibody
11 Jan 2025 //
PR NEWSWIRE
Kelun-Biotech`s TROP2 ADC Approved in China for Advanced TNBC
27 Nov 2024 //
PR NEWSWIRE
Kelun-Biotech’s TROP2-ADC SKB264 NDA Accepted by NMPA
31 Oct 2024 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.